Anesthesia

• Analysis of the factors contributing to residual weakness after sugammadex administration in pediatric patients under 2 years of age
• Sugammadex for our little ones: a brief narrative review
• Statement on Practice Recommendations for Pediatric Anesthesia
• Sugammadex and recurarization in an infant
  
• Sugammadex for reversal of neuromuscular blockade in pediatric patients: Results from a phase IV randomized study
• Smart Tots

Gastroenterology

• Facts About Crypto and Swimming Pools – Patient Handout
• Cryptosporidiosis
• Giardiasis
• For Parents: Treating Pediatric Dehydration
• Swimming Pool Hygiene
• Children’s Health
• GI Kids

Invasive Meningococcal Disease (IMD)

• Long-Term Impacts of Invasive Meningococcal Disease on Survivors and Their Caregivers in the United States and Canada
• AAP: Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, 2026
• US HHS: Childhood Immunization Schedule by Recommendation Group, 2025
• Vaccine for Children Program
• The epidemiology of bacterial meningitis in the United States during 2008–2023: an analysis of active, laboratory, population-based, multistate surveillance data
• ACIP: Meningococcal Vaccination Recommendations, 2020
• Meningococcal Vaccination of Adolescents in the United States: Past Successes and Future Considerations
• Managing Meningococcal Disease Risk in Patients Receiving Complement Inhibitor Therapy
• Yellow Book: Meningococcal Disease
• Addressing Parental Vaccine Hesitancy towards Childhood Vaccines in the United States: A Systematic Literature Review of Communication Interventions and Strategies
• WHO: Communicating about vaccination with caregivers and patients: a communication training module for health workers
• Utilization of Provider-Patient Communication Tools and Approaches to Facilitate Vaccine Confidence: A Systematic Review
• Preventing Meningococcal Disease in US Adolescents and Young Adults Through Vaccination

Psychiatry

• CDC what is ADHD?
• Symptoms of ADHD
• Diagnosing ADHD

Respiratory Syncytial Virus (RSV)

• Protecting Your Baby from RSV: Patient Resource
• Early-life respiratory syncytial virus disease and long-term respiratory health
• The disease burden of respiratory syncytial virus in Infants
• AAP: RSV Prevention Recommendations
• HARMONIE: 180-day efficacy of nirsevimab against hospitalisation for RSV LRTI in infants
• HARMONIE Phase 3b: Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
• MELODY Phase 3: Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
• MATISSE Phase 3: Efficacy, Safety, and Immunogenicity of the Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial
• Preterm Birth Frequency and Associated Outcomes From the MATISSE Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
• CLEVER: Clesrovimab for Prevention of RSV Disease in Healthy Infants
• CDC: Infant RSV Prevention Options
• Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children
• First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants
• Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting
• RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
• The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
• Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months – United States, April 2024
• Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study
• Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment
• CDC: FAQs About RSV Immunization with mAb for Children ≤ 19 Months
• AAP Nirsevimab Administration Visual Guide
• ACOG RSV Prevention Practice Advisory
• For Healthcare Providers: RSV Prevention Information
• MMWR: ACIP Recommendations for Nirsevimab
• MMWR: ACIP Recommendations for Maternal RSV Vaccine
• Nirsevimab Prescribing Information
• Maternal RSV Vaccine Prescribing Information
• Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE)
• Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak
• CDC Recommendations for RSV Prevention
• Patient Brochure: RSV in Infants and Young Children

Vaccine-Preventable Diseases: General

• Communication interventions to reduce parental vaccine hesitancy: A systematic review
• Navigating vaccine hesitancy: Strategies and dynamics in healthcare professional-parent communication
• Pediatric Vaccination – Information for Parents

Vaccine-Preventable Diseases: Influenza

• Estimated Relative Effectiveness and Public Health Impact of Cell‐Based Versus Egg‐Based Influenza Vaccines During the 2022–2023 Season in the United States
• CDC: 2025–2026 Flu Season
• Influenza Activity in the United States during the 2024–2025 Season and Composition of the 2025–2026 Influenza Vaccine
• ACIP Recommendations for Prevention and Control of Influenza in Children, 2025-2026
• Superior Effectiveness and Estimated Public Health Impact of Cell- Versus Egg-Based Influenza Vaccines in Children and Adults During the US 2023–2024 Season
• Relative Vaccine Effectiveness of Cell- vs Egg-Based Quadrivalent Influenza Vaccine Against Test-Confirmed Influenza Over 3 Seasons Between 2017 and 2020 in the United States
• Flu: A Guide for Parents
• Make a Strong Influenza Vaccine Recommendation
• Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing
• Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States

Vaccine-Preventable Diseases: Human Papillomavirus (HPV)

• Top 10 Tips for HPV Vaccination Success
• CDC: ACIP’s HPV Vaccination Recommendations
• CDC: Talking to Parents about HPV Vaccine
• Pediatric Vaccination – Information for Parents
• CDC Resources, Education & References for HPV Vaccination
• Human Papillomavirus Vaccination: ACOG Committee Opinion Vaccination
• HPV Vaccination: What Everyone Should Know
• CDC HPV Vaccine Recommendations
• Standing Order for HPV Vaccine
• Centers for Disease Control and Prevention HPV Vaccine Recommendations
• Recommended Immunization Schedule for Persons Aged 0 Through 18 Years – 2025
• Why Are Childhood Vaccines So Important? – Educational Tool for Parents